In addition to the combination of anti-CD47 with regular chemotherapy, it can also be used with biologics, such as combining CD47 blockade with trastuzumab, which eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance [43]. The gene discussed is CD47; the disease is breast carcinoma.